perillyl alcohol
Perilla alcohol is a naturally occurring monoterpene related to limonene. It is isolated from the essential oils of lavender, peppermint, spearmint, cherries, celery seeds, and several other plants. It has been used topically as a mosquito repellant and in toiletries and may be touted as a constituent of natural products such as tart cherry juice. Perillyl alcohol has demonstrated antiangiogenesis and anticancer effects in vitro. Purported mechanism of action is suppression of the synthesis of small G proteins, including RAS, thereby arresting tumor cells in the G1 phase of the cell cycle. Early clinical studies did not efficacy in prostate, ovarian or breast cancer, probably due to bad pharmacokinetic properties and toxicity after oral administration. More recent preliminary studies found intranasal delivery in patients with malignant gliomas to be well-tolerated and effective, with one study reporting tumor size regression, and another reporting increased overall survival and no side effects after long-term use. — NCATS
Clinical trial activity
9 trials · 9 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 1996 (NCT00002862)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 1
- Brain Stem Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Central Nervous System Neoplasms · Phase 1
- Glioblastoma · Phase 1/Phase 2
- Glioma · Phase 1
- Lymphoma · Phase 1
- Meningioma · Phase 2
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 2
- Pinealoma · Phase 1
- Precancerous Conditions · Phase 2
- Prostatic Neoplasms · Phase 2
- Spinal Cord Neoplasms · Phase 1
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
SMILES
CC(=C)[C@H]1CCC(CO)=CC1- Mol. weight
- 152.2334 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPerillyl alcohol ↗
- NCATS3UL4QIY642 ↗
- ChEMBLCHEMBL236687 ↗
Also known as
- 1-cyclohexene-1-methanol, 4-(1-methylethenyl)-, (4s)-
- 4-isopropenyl-cyclohex-1-ene-1-methanol
- cyclohex-1-ene-1-methanol, 4(1-methylethenyl)
- dihydrocuminyl alcohol
- nsc 641066
- perilla alcohol
- perilla alcohol, (r)-isomer
- perilla alcohol, (s)-isomer
- perillyl alcohol
- perillyl alcohol
- perillyl alcohol
- (-)-p-mentha-1,8-dien-7-ol
- p-mentha-1,8-dien-7-ol
- (s)-perillyl alcohol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06357377 | Phase 1 | Dec 31, 2024 | NeOnc Technologies |
| NCT05023018 | Phase 2 | Oct 1, 2021 | NeOnc Technologies |
| NCT02704858 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | ClinDatrix, Inc., NeOnc Technologies |
| NCT00608634 | Phase 2 | May 1, 2004 | National Cancer Institute (NCI), State of Arizona, University of Arizona |
| NCT00022425 | Phase 1 | Jun 1, 2001 | National Cancer Institute (NCI), University of Rochester |
| NCT00003769 | Phase 2 | Feb 1, 1999 | Indiana University, National Cancer Institute (NCI) |
| NCT00003219 | Phase 2 | May 1, 1998 | National Cancer Institute (NCI), University of Wisconsin |
| NCT00003238 | Phase 2 | Feb 1, 1998 | National Cancer Institute (NCI), University of Wisconsin |
| NCT00002862 | Phase 1 | Oct 1, 1996 | National Cancer Institute (NCI), Yale University |
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 6 | 1 | 2 | 1996 |
| NeOnc Technologies | For profit | 3 | 3 | 2 | 2016 |
| University of Wisconsin | Academic/Hospital | 2 | 2 | 1 | 1998 |
| ClinDatrix, Inc. | For profit | 1 | 0 | 1 | 2016 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| State of Arizona | Government | 1 | 0 | 1 | 2004 |
| University of Arizona | Academic/Hospital | 1 | 1 | 1 | 2004 |
| University of Rochester | Academic/Hospital | 1 | 1 | 1 | 2001 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 1996 |